CTI Expands Clinical Research Network Through Acquisition of SRI Clinical Trial Unit; Organizations Launch Strategic Research Partnership

Government and commercial clients will benefit from expanded capabilities and operations

FOR IMMEDIATE RELEASE [Covington, KY and Menlo Park, CA ~ 4 August 2026]

CTI Clinical Trial and Consulting Services (CTI), a global, privately held, full-service contract research organization, and SRI, an independent nonprofit research institute, today announced a strategic partnership that includes CTI's acquisition of SRI's Clinical Trial Unit in Plymouth, Michigan. The site will become part of CTI's growing clinical research network and operate as CTI Clinical Research Center Michigan.

Established in 2014 and located within the Michigan Life Science Innovation Center, SRI's Clinical Trial Unit has supported commercial and federally funded research programs across a range of therapeutic areas including vaccines, neurology, and pain studies. In 2023, the site hosted the first-in-human Phase 1 clinical trial of HOPO 14-1, a novel oral treatment for radioactive contamination funded by the NIH's National Institute of Allergy and Infectious Diseases.

"For over a decade, our clinical trials team has been involved in impactful advancements," said Kathlynn Brown, President of SRI's Biosciences Division. "We're excited about the opportunities this new collaboration creates for SRI and CTI going forward. Through this partnership SRI will have broader access to resources from the CTI network that allows us to expand our offerings to our partners both government and commercial."

The acquisition builds upon the success of CTI Clinical Research Center Ohio, a leading early-phase research center recognized for its expertise in vaccines, infectious disease, sleep, metabolic diseases, wearables, and other technology-enabled research. Located in Cincinnati, OH, the site has a 30+ year history of advancing clinical research and features a 30-bed Phase I unit, as well as a robust later-phase services supporting Phase II, III, and IV studies.

"This is an important step in CTI's long-term growth strategy," said Brian Lawrence, CTI Chief Financial Officer and President. "The Michigan team brings an impressive track record of clinical research excellence. We're excited to welcome them to CTI, expand our site network with additional expertise, and begin a strategic partnership with SRI."

Beyond the acquisition, CTI and SRI intend to pursue opportunities for collaboration across research and clinical development. Through the combination of SRI's longstanding scientific and government research experience with CTI's global clinical trial execution expertise, the organizations are positioned to support commercial and federally funded research programs, advancing innovative therapies for patients together. As part of the partnership, SRI will have priority access to CTI Clinical Research Center Michigan as well as other sites within the CTI network to support ongoing and future clinical research activities.

To learn more about CTI Clinical Research Center Michigan or explore current clinical trial opportunities, visit ctifacts.com.